KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Preferred Stock Liabilities (2017)

Historic Preferred Stock Liabilities for Bionano Genomics (BNGO) over the last 1 years, with Q4 2017 value amounting to $31.4 million.

  • Bionano Genomics' Preferred Stock Liabilities changed N/A to $31.4 million in Q4 2017 from the same period last year, while for Dec 2017 it was $31.4 million, marking a year-over-year change of. This contributed to the annual value of $31.4 million for FY2017, which is N/A changed from last year.
  • Latest data reveals that Bionano Genomics reported Preferred Stock Liabilities of $31.4 million as of Q4 2017.
  • Bionano Genomics' Preferred Stock Liabilities' 5-year high stood at $31.4 million during Q4 2017, with a 5-year trough of $31.4 million in Q4 2017.